Chinese domestic crown disease treatment oral drug SIM0417 has completed the clinical clinical period, it is expected to be launched as soon as February 2023EssenceNot According to the WeChat public account of the Jiangsu Drug Administration on Monday (December 26), the Jiangsu Provincial Drug Administration recently held a special scheduling meeting for the SIM0417 Research Progress of the Crown Diseases of the Vonential Pharmaceutical Industry, so as to use it withAccelerate the progress of the listing of crown diseases in Jiangsu Province.Not Announcement shows that SIM0417 is a new 3CL target new crown therapeutic oral medicine jointly developed by the Shanghai Pharmaceutical Research Institute and Wuhan Virus Research Institute.The State Drug Administration has clinical approval and has been included in the key directory of the scientific research of the joint prevention and control mechanism of the State Council.Not Announcement also said that the third phase of the SIM0417 project has completed the group of 1,208 patients on December 16th, and the progress is first in the domestic 3CL target drug. It is expected to be listed as soon as February 2023.EssenceNot Jiang Wei, deputy director of the Jiangsu Provincial Drug Administration, said that SIM0417 is a major innovative drug for the new crown of autonomous intellectual property rights in Jiangsu Province, which is of great significance for the current prevention and control of the Jiangsu Province.Enterprises must step up the progress of research and development, further strengthen the management of research process, ensure science and compliance, actively carry out communication with the Pharmaceutical Examination Center of the State Drug Administration, and plan in advance, and consider the expansion of production capacity after being approved for listing.Not Jiang Wei said that for the needs of the need for coordination and support proposed by the pioneer pharmaceutical industry, the Provincial Drug Administration will go all out to continue to increase communication and application for assistance, and handle review and approval at full speed., Check the inspection and other matters to help SIM0417 get approved as soon as possible.Not After the control measures of the crown disease epidemic, antiviral oral drugs were out of stock in many places.Paxlovid of Pfizer's crown disease oral drugs and Molnupiravir, a crown disease oral oral drug in Merck, have all flowed into the Chinese market and sold circulation in the black market.In order to increase the supply of oral drugs, Japan's Yanye Pharmaceutical Company announced on Friday (23rd) that it signed an agreement with Chinese companies Xocova.
